证券之星消息，截至2025年11月24日收盘，迈得医疗(688310)报收于15.48元，上涨1.84%，换手率 2.38%，成交量3.95万手，成交额6096.08万元。 11月24日的资金流向数据方面，主力资金净流出1039.01万元，占总成交额17.04%，游资资金净流入 283.9万元，占总成交额4.66%，散户资金净流入755.1万元，占总成交额12.39%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-24 | 15.48 | 1.84% | -1039.01万 | -17.04% | 283.90万 | 4.66% | 755.10万 | - 12.39% | | 2025-11-21 | 15.20 | -4.64% | -273.92万 | -5.86% | 217.70万 | 4.65% | 56.22万 | 1.20% | | 2025-11-20 | ...

Core Insights - The stock of Maide Medical (688310) closed at 17.37 yuan on November 10, 2025, with a rise of 2.24% and a trading volume of 39,500 hands, resulting in a transaction amount of 67.74 million yuan [1] Financial Performance - For the first three quarters of 2025, Maide Medical reported a main business revenue of 225 million yuan, an increase of 2.31% year-on-year, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main business revenue of 83.64 million yuan, a year-on-year increase of 54.38%, and a net profit attributable to shareholders of 2.79 million yuan, up 224.07% year-on-year [3] - The company's gross profit margin stands at 40.19%, while the net profit margin is -2.43% [3] Market Position - Maide Medical's total market capitalization is 2.887 billion yuan, with a net asset value of 840 million yuan and a net profit of 8.84 million yuan [3] - The company has a price-to-earnings ratio (P/E) of 245.05, which is significantly higher than the industry average of 142.9 [3] - In terms of industry ranking, Maide Medical is positioned 219th in total market value and 200th in net assets among 270 companies in the specialized equipment industry [3] Capital Flow Analysis - On November 10, 2025, the net outflow of main funds was 2.65 million yuan, accounting for 3.92% of the total transaction amount, while retail investors saw a net inflow of 6.06 million yuan, representing 8.94% of the total transaction amount [1][2] - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from main and speculative funds on several days [2]

Core Viewpoint - The stock of Maide Medical (688310) has shown a slight increase of 1.9% on October 31, 2025, closing at 19.33 yuan, with notable fluctuations in capital flow indicating mixed investor sentiment [1][2]. Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 83.64 million yuan, reflecting a significant year-on-year increase of 54.38%, and a net profit of 2.79 million yuan, which is a remarkable rise of 224.07% year-on-year [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 1.87 million yuan, accounting for 3.32% of the total transaction amount, while retail investors saw a net inflow of 664,600 yuan, representing 1.18% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net inflows and outflows from different investor categories [2]. Industry Comparison - Maide Medical's total market value stands at 3.213 billion yuan, which is below the industry average of 7.798 billion yuan, ranking 205th out of 269 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) is 272.7, significantly higher than the industry average of 146.16, indicating a potential overvaluation compared to peers [3]. Company Overview - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, integrating technology in medical device processes, automation, and software to provide comprehensive solutions for medical consumable manufacturers [3].

Core Viewpoint - Midea Medical, established in 2003 and listed in 2019, specializes in the research, production, and sales of medical consumables and intelligent equipment, holding several patents in the field [1]. Group 1: Business Performance - For Q3 2025, Midea Medical reported revenue of 225 million yuan, ranking 21st among 25 companies in the industry, with the industry leader achieving 3.653 billion yuan [2]. - The net profit for the same period was -5.46 million yuan, placing the company 18th in the industry, while the top performer reported a net profit of 417 million yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Midea Medical's debt-to-asset ratio was 29.86%, lower than the industry average of 35.98% [3]. - The gross profit margin for Q3 2025 was 40.19%, which is above the industry average of 33.21% [3]. Group 3: Executive Compensation - The chairman, Lin Junhua, received a salary of 1.3803 million yuan in 2024, an increase of 909,300 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 19% to 4,528, while the average number of shares held per shareholder decreased by 15.97% to 36,700 shares [5]. Group 5: Future Outlook - According to Guosheng Securities, Midea Medical's performance in the first half of 2025 declined due to fluctuations in downstream demand, but showed significant improvement in Q2 [6]. - The company has a strong order backlog for new products, with 21 units of drug-device combination products expected to drive growth [6]. - Revenue projections for 2025 to 2027 are 501 million, 606 million, and 734 million yuan, with corresponding net profits of 80 million, 108 million, and 131 million yuan, indicating substantial growth [6].

Core Insights - The stock of Maide Medical (688310) closed at 20.9 yuan on October 24, 2025, with a 1.36% increase and a trading volume of 19,500 lots, amounting to a total transaction value of 40.54 million yuan [1] Financial Performance - For the first half of 2025, Maide Medical reported a main revenue of 141 million yuan, a year-on-year decrease of 14.75% - The net profit attributable to shareholders was 6.0451 million yuan, down 38.81% year-on-year - The non-recurring net profit was -2.5149 million yuan, a decline of 135.52% year-on-year - In Q2 2025, the company achieved a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year - The single-quarter net profit attributable to shareholders was 16.8424 million yuan, a significant increase of 2759.64% year-on-year - The single-quarter non-recurring net profit was 11.8767 million yuan, up 923.08% year-on-year [3] Market Position - Maide Medical's total market capitalization is 3.474 billion yuan, compared to the industry average of 7.749 billion yuan, ranking 188 out of 268 in the specialized equipment industry - The company's net assets stand at 828 million yuan, with an industry average of 2.253 billion yuan, ranking 200 out of 268 - The net profit of 6.0451 million yuan places the company at 193 out of 268 in the industry, with a price-to-earnings ratio of 287.34, significantly higher than the industry average of 51.37, ranking 191 out of 268 - The price-to-book ratio is 4.34, compared to the industry average of 3.97, ranking 169 out of 268 - The gross margin is 38.93%, above the industry average of 27.83%, ranking 43 out of 268 - The net margin is -1.29%, below the industry average of 0.66%, ranking 215 out of 268 - The return on equity (ROE) is 0.76%, compared to the industry average of 2.21%, ranking 190 out of 268 [3] Investment Sentiment - In the last 90 days, one institution has given a rating of "buy" for Maide Medical [4]

Core Viewpoint - The stock of Maide Medical (688310) has shown a decline in price and mixed capital flow, indicating potential challenges in market performance and investor sentiment [1][2]. Financial Performance - As of October 22, 2025, Maide Medical's stock closed at 20.88 yuan, down 0.67% with a trading volume of 27,500 hands and a transaction amount of 57.62 million yuan [1]. - The company's main revenue for the first half of 2025 was 141 million yuan, a year-on-year decrease of 14.75%, while the net profit attributable to shareholders was 6.05 million yuan, down 38.81% year-on-year [3]. - The second quarter of 2025 showed a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year, and a net profit of 16.84 million yuan, up 2759.64% year-on-year [3]. Capital Flow Analysis - On October 22, 2025, the net inflow of main funds was 3.99 million yuan, accounting for 6.93% of the total transaction amount, while retail investors saw a net inflow of 2.47 million yuan, representing 4.29% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from speculative funds on several days [2]. Industry Comparison - Maide Medical's total market value is 3.471 billion yuan, significantly lower than the industry average of 7.648 billion yuan, ranking 186 out of 268 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) stands at 287.07, compared to the industry average of 48.9, indicating a high valuation relative to earnings [3]. - The gross profit margin of Maide Medical is 38.93%, which is above the industry average of 27.76%, but the net profit margin is negative at -1.29%, compared to a positive 0.54% industry average [3].

Group 1 - The stock price of Maide Medical (688310) closed at 18.74 yuan on August 28, 2025, down 2.55% with a turnover rate of 5.95% and a trading volume of 98,900 hands, resulting in a transaction amount of 191 million yuan [1] - The net inflow of main funds on August 28 was 1.2183 million yuan, accounting for 0.64% of the total transaction amount, while retail investors had a net inflow of 1.2535 million yuan, also accounting for 0.65% [1] - The company reported a main business income of 141 million yuan for the first half of 2025, a year-on-year decrease of 14.75%, and a net profit attributable to shareholders of 6.0451 million yuan, down 38.81% year-on-year [4] Group 2 - The financing data on August 28 showed a financing balance of 87.245 million yuan, with a net repayment of 15.0958 million yuan [2] - The company’s total market value is 3.115 billion yuan, with a net asset of 828 million yuan and a net profit of 6.0451 million yuan, ranking 202nd, 198th, and 185th respectively in the specialized equipment industry [4] - The gross profit margin of Maide Medical is 38.93%, which is higher than the industry average of 27.56% [4]

Core Insights - The company reported a revenue of 141 million yuan and a net profit attributable to shareholders of 6.0451 million yuan for the first half of 2025, with a significant increase in net cash flow from operating activities by 243.9% year-on-year [1] - In the second quarter, the company achieved a revenue of 101 million yuan and a net profit of 16.8424 million yuan, marking a substantial turnaround from previous losses [1] Business Overview - The main business of the company includes the research, production, sales, and service of medical consumables and intelligent equipment, focusing on safety infusion and blood purification devices [1] - The company is actively expanding its second growth curve through its subsidiary, Zhejiang Maide Shun Contact Lens Co., Ltd., by advancing its contact lens business and developing related materials and products [1] Production Capacity and Strategy - The company currently operates four production lines for contact lenses, each with an annual capacity of 18 million pieces, and plans to dynamically adjust production capacity based on market conditions as the business commercializes [2] - The company has a unique advantage in production, as it manufactures its own equipment, allowing for continuous improvement and cost optimization, unlike competitors who must purchase equipment [2] Order and Contract Status - As of the end of 2024, the company has 21 orders for its drug-device combination products, which are expected to be a new growth point for performance [2] - The company's contract liabilities exceeded 180 million yuan in the first half of the year, representing an increase of 83.28% compared to the end of the previous year, indicating a rise in advance payments for orders [2]

Core Viewpoint - The stock of Maide Medical (688310) has experienced a significant decline, with a closing price of 19.23 yuan on August 27, 2025, down 6.24% from the previous day, indicating a volatile trading environment and mixed investor sentiment [1] Financial Performance - For the first half of 2025, Maide Medical reported a main revenue of 141 million yuan, a year-on-year decrease of 14.75% - The net profit attributable to shareholders was 6.0451 million yuan, down 38.81% year-on-year - The net profit after deducting non-recurring items was -2.5149 million yuan, a decline of 135.52% year-on-year [5] Quarterly Performance - In Q2 2025, the company achieved a single-quarter main revenue of 101 million yuan, an increase of 10.58% year-on-year - The single-quarter net profit attributable to shareholders was 16.8424 million yuan, a substantial increase of 2759.64% year-on-year - The single-quarter net profit after deducting non-recurring items was 11.8767 million yuan, up 923.08% year-on-year [5] Market Position - Maide Medical's total market capitalization is 3.196 billion yuan, significantly lower than the industry average of 7.605 billion yuan, ranking 197 out of 265 in the specialized equipment industry - The company's net assets stand at 828 million yuan, compared to the industry average of 2.252 billion yuan, ranking 198 out of 265 [5] Key Financial Ratios - The price-to-earnings (P/E) ratio is 264.38, much higher than the industry average of 72.24, ranking 185 out of 265 - The price-to-book (P/B) ratio is 3.99, slightly above the industry average of 3.84, ranking 152 out of 265 - The gross margin is 38.93%, significantly higher than the industry average of 27.5%, ranking 41 out of 265 - The net margin is -1.29%, worse than the industry average of -0.41%, ranking 209 out of 265 - Return on equity (ROE) is 0.76%, lower than the industry average of 1.76%, ranking 177 out of 265 [5] Trading Activity - On August 27, 2025, the stock had a trading volume of 144,700 hands and a total transaction amount of 289 million yuan - The net inflow of main funds was 13.4688 million yuan, accounting for 4.67% of the total transaction amount, while retail investors saw a net outflow of 1.4399 million yuan, representing 0.5% of the total transaction amount [1][2] Margin Trading - On August 27, 2025, the margin trading data showed a financing balance of 102 million yuan, with a net financing purchase of 30.2464 million yuan - There were no short sales or repayments recorded, indicating a stable margin trading environment [3]

Core Viewpoint - The stock of Maide Medical (688310) has shown a significant increase of 4.67% on August 21, 2025, closing at 18.59 yuan, despite a net outflow of major funds [1][2]. Financial Performance - Maide Medical reported a main revenue of 40.18 million yuan for Q1 2025, a year-on-year decline of 45.87% [4]. - The net profit attributable to shareholders was -10.80 million yuan, representing a year-on-year decrease of 202.7% [4]. - The company’s gross profit margin stands at 32.89%, which is higher than the industry average of 27.3% [4]. Market Position - The total market capitalization of Maide Medical is 3.09 billion yuan, significantly lower than the industry average of 7.58 billion yuan [4]. - The company ranks 202nd out of 265 in terms of total market value within the specialized equipment industry [4]. - The price-to-earnings ratio (P/E) is -71.55, indicating negative earnings, while the industry average is 81.71 [4]. Fund Flow Analysis - On August 21, 2025, the net outflow of major funds was 2.41 million yuan, accounting for 1.89% of the total transaction amount [1]. - Retail investors showed a net inflow of 2.95 million yuan, representing 2.30% of the total transaction amount on the same day [1]. - Over the past five days, the trend indicates a consistent net outflow from major funds, with a total net outflow of 4.43 million yuan on August 20, 2025 [1][2]. Financing and Margin Trading - As of August 21, 2025, the financing balance is 68.97 million yuan, with a net repayment of 10.46 million yuan on that day [2]. - There were no shares sold or repaid in the margin trading segment, indicating no activity in this area [2].